Pages that link to "Q33906140"
Jump to navigation
Jump to search
The following pages link to Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases (Q33906140):
Displaying 50 items.
- Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase (Q24307789) (← links)
- Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells (Q24603941) (← links)
- EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib (Q24606177) (← links)
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (Q24646295) (← links)
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes (Q24647928) (← links)
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (Q24649549) (← links)
- A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours (Q24653999) (← links)
- The selectivity of protein kinase inhibitors: a further update (Q24654622) (← links)
- Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach (Q24672143) (← links)
- Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency (Q24681743) (← links)
- ErbB receptors: from oncogenes to targeted cancer therapies (Q24683709) (← links)
- An unexpected but interesting response to a novel therapy for malignant extragastrointestinal stromal tumor of the mesoileum: a case report and review of the literature (Q27013797) (← links)
- Structure-guided development of affinity probes for tyrosine kinases using chemical genetics (Q27643967) (← links)
- Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases (Q27658863) (← links)
- Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor (Q27851455) (← links)
- Ponatinib in refractory Philadelphia chromosome-positive leukemias (Q27851967) (← links)
- Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study (Q27852657) (← links)
- Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? (Q28081844) (← links)
- Cell cycle kinases as therapeutic targets for cancer (Q28250447) (← links)
- Development of novel ACK1/TNK2 inhibitors using a fragment-based approach (Q28257452) (← links)
- A quantitative analysis of kinase inhibitor selectivity (Q28264038) (← links)
- ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation (Q28289188) (← links)
- Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia (Q28474737) (← links)
- Aurora kinases as targets in drug-resistant neuroblastoma cells (Q28543446) (← links)
- Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution (Q28548366) (← links)
- Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation (Q28552585) (← links)
- BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (Q28756824) (← links)
- Synthetic and Biological Studies of Sesquiterpene Polygodial: Activity of 9-Epipolygodial against Drug-Resistant Cancer Cells (Q28834689) (← links)
- Targeting cancer with small molecule kinase inhibitors (Q29547395) (← links)
- Epidermal growth factor receptor mutations in lung cancer (Q29615474) (← links)
- Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases (Q30433918) (← links)
- Nanotechnology and cancer (Q30452478) (← links)
- Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors (Q33396953) (← links)
- Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases (Q33509846) (← links)
- Emerging drugs for chronic myeloid leukemia (Q33536762) (← links)
- Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques (Q33612912) (← links)
- Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases (Q33631185) (← links)
- Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling (Q33753325) (← links)
- Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study (Q33756542) (← links)
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor (Q33810574) (← links)
- Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer (Q33810641) (← links)
- Targeting the cancer kinome through polypharmacology (Q33893019) (← links)
- A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis (Q33897070) (← links)
- Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy (Q33918198) (← links)
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors (Q34005966) (← links)
- Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia (Q34016866) (← links)
- A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl (Q34052015) (← links)
- A structure-guided approach to creating covalent FGFR inhibitors (Q34061522) (← links)
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase (Q34068377) (← links)
- The resurgence of covalent drugs (Q34174891) (← links)